April’s FDA approvals feature first-in-class therapies, targeted biologics, expanded indications, and innovative delivery systems across allergy, endocrinology, rheumatology, oncology, infectious diseases, and more.
Researchers combined spatial transcriptomics with machine learning to develop a urine-based prostate cancer test with 92% accuracy, outperforming traditional PSA testing.
Individuals who reported a neutral level of satisfaction with their sense of belonging were approximately 3 times more likely to express an intent to leave, while those who were dissatisfied were 7 times more likely to do so, compared to individuals who were satisfied with their sense of belonging.
SAHaRA trial investigators compared a liberal (transfusion at hemoglobin levels of 10 g/dL or lower) and a restrictive (transfusion at 8 g/dL or lower) red-cell tranfusion strategy among critically ill patients with acute aneurysmal subarachnoid hemorrhage (SAH) and anemia.
Conexiant
Daily News
Stay up to date with the latest clinical headlines and other information tailored to your specialty.
Thank you for signing up for the Daily News alerts. You will begin receiving them shortly.
The FDA approves vutrisiran (Amvuttra) as the first RNAi therapeutic to reduce cardiovascular events and mortality in adults with transthyretin-mediated (ATTR) amyloidosis with cardiomyopathy.
Preclinical study demonstrates that aspirin may prevent cancer metastasis by inhibiting platelet-produced TXA2, which normally suppresses T-cell immunity against spreading cancer cells.